Back
eGain Corp. 10K Form
Sell
30
EGAN
eGain Corp.
Last Price:
$10.53
Seasonality Move:
7.25%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-09 | 10Q | EGAN/eGain Corp. Quarterly |
| 2024-02-08 | 10Q | EGAN/eGain Corp. Quarterly |
| 2023-11-07 | 10Q | EGAN/eGain Corp. Quarterly |
| 2023-05-11 | 10Q | EGAN/eGain Corp. Quarterly |
| 2023-02-14 | 10Q | EGAN/eGain Corp. Quarterly |
| 2022-11-14 | 10Q | EGAN/eGain Corp. Quarterly |
Receive EGAN News And Ratings
See the #1 stock for the next 7 days that we like better than EGAN
EGAN Financial Statistics
Sales & Book Value
| Annual Sales: | $88.4M |
|---|---|
| Cash Flow: | $10.2M |
| Price / Cash Flow: | 21.08 |
| Annual Sales: | $3.10 |
| Price / Book: | 3.4 |
Profitability
| EPS (TTM): | 1.24000 |
|---|---|
| Net Income (TTM): | $34.4M |
| Gross Margin: | $60.6M |
| Return on Equity: | 52.65% |
| Return on Assets: | 27.52% |
eGain Corp. Earnings Forecast
Key eGain Corp. Financial Ratios
-
The Gross Profit Margin over the past 28 years for EGAN is 68.52%.
-
The Selling, General & Administrative Expenses for EGAN have been equal to 31.63% of Gross Profit Margin.
-
The Research & Development expenses have been 33.48% of Revenue.
-
The Interest Expense is 0.00% of Operating Income.
-
The Net Earning history of EGAN is 36.47% of Total Revenues.
-
Per Share Earnings over the last 28 years have been positive in 17 years.
eGain Corp. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Software |
| Sector: | Information Technology |
| Current Symbol: | EGAN |
| CUSIP: | 28225C |
| Website: | egain.com |
Debt
| Debt-to-Equity Ratio: | 0.04 |
|---|---|
| Current Ratio: | 1.74 |
| Quick Ratio: | 1.69 |
Price-to-Earnings
| Trailing P/E Ratio: | 9.34 |
|---|---|
| Forward P/E Ratio: | 28.79 |
EGAN Technical Analysis vs Fundamental Analysis
Sell
30
eGain Corp. (EGAN)
is a Sell
Is eGain Corp. a Buy or a Sell?
-
eGain Corp. stock is rated a SellThe current eGain Corp. [EGAN] share price is $10.51. The Score for EGAN is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.